Related Experiment Video

Updated: Jun 4, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Targeted therapies for metastatic esophagogastric cancer

Deepa Reddy1, Zev A Wainberg

  • 1UCLA Department of Hematology and Oncology, Los Angeles, CA 90095, USA.

Current Treatment Options in Oncology
|February 8, 2011
PubMed

Insights

Prognosis for metastatic esophagogastric cancer (EGC) is poor, with chemotherapy as the main treatment. Targeted therapies, like trastuzumab, show promise but only benefit a subset of patients, necessitating research into new pathways.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Metastatic esophagogastric cancer (EGC) has a poor prognosis and limited long-term survival.
  • Traditional treatment relies on combination chemotherapy.
  • Emerging targeted therapies aim to improve patient outcomes.

Purpose of the Study:

  • To review the current landscape of targeted therapies for metastatic EGC.
  • To highlight the limitations of existing treatments and the need for novel therapeutic strategies.
  • To discuss the potential of targeting other pathways in EGC treatment.

Main Methods:

  • Literature review of clinical trials and research studies on EGC targeted therapies.
  • Analysis of HER2/Neu oncogene amplification in EGC.
  • Exploration of emerging therapeutic targets and pathways in EGC.

Main Results:

  • Trastuzumab, a HER2-targeted therapy, is the only approved targeted agent for EGC.
  • HER2 amplification is present in only a small fraction of EGC patients.
  • Several other clinically relevant pathways are under investigation for EGC treatment.

Conclusions:

  • Current targeted therapies offer benefit to a limited patient population.
  • Further research into novel molecular targets and pathways is crucial for advancing EGC treatment.
  • The development of new targeted therapies holds promise for improving survival rates in metastatic EGC.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.